IP Library Granted Patent US 7,374,745
Granted Patent B2
US 7,374,745 · App. 10/798,486 · Granted May 20, 2008

Ultrasound contrast agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,374,745
App. No.
10/798,486
Granted
May 20, 2008
Kind
B2
Abstract

New ultrasound contrast agents that comprise microbubbles encapsulating a gas within a shell made from a blend of bipolar compounds having mixed carbon chain length. The compounds have hydrophobic groups selected from the group consisting of straight-chained alkyls, alkylethers, alkylthiolethers, alkyldisulfides, polyfluoroalkyls, and polyfluoroalkylethers having a carbon chain length greater than or equal to 16 and less than or equal to 32. The polar groups are connected to the hydrophobic groups by means of a linker. The polar head groups are selected from the group consisting of CO 2 -M + , SO 3 − M + , SO 4 − M + , PO 3 − M + , PO 4 − M + 2 , N(R) 4 + , a pyridinium or substituted pyridinium group, and a zwitterionic group; R is selected from the group consisting of —H, —CH 3 , alkyl, cycloalkyl, substituted cycloalkyls containing one or more heteroatoms, and benzyl and can be the same or different; and Z′ is a nonionic and M is a cation.

Claims (19)

1. A biocompatible composition comprising microbubbles encapsulating a gas within a shell comprising a plurality of compounds, each compound having a polar head group linked to a straight-chain hydrophobic group selected as having different chain lengths sufficient for longer chains to assemble beneath adjacent shorter chains thereby enhancing rigidity of the shell, the hydrophobic groups oriented toward the gas, wherein the compounds have the structure

R 1 —X-Z;

R 2 —X-Z;

and R 3 —X-Z′

where R 1 , R 2 and R 3 are hydrophobic groups selected from the group consisting of straight-chain alkyls, alkylethers, alkylthiolethers, alkyldisulfides, polyfluoroalkyls, and polyfluoroalkylethers having a carbon chain length greater than or equal to 16 and less than or equal to 32 and where R 1 is greater than R 2 and R 1 is greater than or equal to R 3 ; R 3 has one or more such hydrophobic groups having the same or different lengths; X is a linker connecting the hydrophobic group to the polar head group; Z is a polar head group selected from the group consisting of CO 2 -M + , SO 3 − M + , SO 4 − M + , PO 3 − M + , PO 4 − M + 2 , N(R) 4 + , a pyridinium or substituted pyridinium group, and a zwitterionic group; R is selected from the group consisting of —H, —CH 3 , alkyl, cycloalkyl, substituted cycloalkyls containing one or more heteroatoms, and benzyl and can be the same or different; and Z′ is a nonionic group selected from the group consisting of polysorbates, polyglycerols, polypeptides, polynucleotides, polysaccharides, polyvinylpyrrolidones, polyvinylalcohols, polyethyleneglycols, and combinations thereof.

2. The composition of claim 1 wherein R 1 , R 2 and R 3 are straight-chain alkyl groups having from about 20 to 30 carbon atoms.

3. The composition of claim 1 wherein X is selected from the group consisting of —(CH 2 ) m —, —(CH 2 ) m CO 2 (CH 2 ) n —, —(CH 2 ) m CONH(CH 2 ) n —, —(CH 2 ) m NHCONH(CH 2 ) n —, —(CH 2 ) m OCONH(CH 2 ) n —, —(CH 2 ) m O(CH 2 ) n —, —(CH 2 ) m NH(CH 2 ) n —, —(CH 2 ) m N[(CH 2 ) m ] 2 —, —(CH 2 ) m S(CH 2 ) n —, —(CH 2 ) m —, —(CH 2 ) m SO(CH 2 ) n —, —(CH2) m SO 2 (CH 2 ) n —, —(CH 2 ) m NH(CH 2 ) n CO 2 (CH 2 ) o —, —[(CH 2 ) m ] 2 N(CH 2 ) n CONH(CH 2 ) o —, where m, n, and o are the same or different and are less than 5, DL-Iysine, aspartic acid, glutamic acid, serine, cysteine, homocysteine, cystine, serinol, itaconic acid, tigilic acid, maleic acid, DL-malic acid, succinic acid, tartaric acid, malonic acid, citric acid, phthalic acid, terephthalic acid, N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid, N,N-bis(2-hydroxyethyl)glycine, 3-[N,N-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, N-tris[hydroxylmethyl]methyl-3-aminopropanesulfonic acid, and N-tris[hydroxylmethyl]glycine.

4. The composition of claim 1 wherein Z′ is poly(ethyleneglycol) with the number of ethyleneglycol monomer units greater than or equal to 20.

5. A method for obtaining an ultrasound contrast image of body tissue comprising:

administering into a body a biocompatible composition useful as an ultrasound contrast agent comprising microbubbles encapsulating a gas within a shell comprising a plurality of compounds, each compound having a polar head group linked to a straight-chain hydrophobic group selected as having different chain lengths sufficient for longer chains to assemble beneath adjacent shorter chains thereby enhancing rigidity of the shell, the hydrophobic groups oriented toward the gas wherein the compounds have the structure:

R 1 —X-Z;

R 2 —X-Z;

and R 3 —X-Z′

where R 1 , R 2 and R 3 are hydrophobic groups selected from the group consisting of straight-chain alkyls, alkylethers, alkylthiolethers, alkyldisulfides, polyfluoroalkyls, and polyfluoroalkylethers having a carbon chain length greater than or equal to 16 and less than or equal to 32 and where R 1 is greater than R 2 and R 1 is greater than or equal to R 3 ; R 3 has one or more such hydrophobic groups having the same or different lengths; X is a linker connecting the hydrophobic group to the polar head group; Z is a polar head group selected from the group consisting of CO 2 -M + , SO 3 − M + , SO 4 − M + , PO 3 − M + , PO 4 − M + 2 , N(R) 4 + , a pyridinium or substituted pyridinium group, and a zwitterionic group; R is selected from the group consisting of —H, —CH 3 , alkyl, cycloalkyl, substituted cycloalkyls containing one or more heteroatoms, and benzyl and can be the same or different; and Z′ is a nonionic group selected from the group consisting of polysorbates, polyglycerols, polypeptides, polynucleotides, polysaccharides, polyvinylpyrrolidones, polyvinylalcohols, polyethyleneglycols, and combinations thereof, and

taking an ultrasound image of the desired tissue.

6. The method of claim 5 wherein R 1 , R 2 and R 3 are straight-chain alkyl groups having from about 20 to 30 carbon atoms.

7. The method of claim 5 wherein X is selected from the group consisting of —(CH 2 ) m —, —(CH 2 ) m CO 2 (CH 2 ) n —, —(CH 2 ) m CONH(CH 2 ) n —, —(CH 2 ) m NHCONH(CH 2 ) n —, —(CH 2 ) m OCONH(CH 2 ) n —, —(CH 2 ) m O(CH 2 ) n —, —(CH 2 ) m NH(CH 2 ) n —, —(CH 2 ) m N[(CH 2 ) m ] 2 —, —(CH 2 ) m S(CH 2 ) n —, —(CH 2 ) m —, —(CH 2 ) m SO(CH 2 ) n —, —(CH 2 ) m SO 2 (CH 2 ) n —, —(CH 2 ) m NH(CH 2 ) n CO 2 (CH 2 ) o —, —[(CH 2 ) m ] 2 N(CH 2 ) n CONH(CH 2 ) o —, where m, n, and o are the same or different and are less than 5, DL-lysine, aspartic acid, glutamic acid, serine, cysteine, homocysteine, cystine, serinol, itaconic acid, tigilic acid, maleic acid, DL-malic acid, succinic acid, tartaric acid, malonic acid, citric acid, phthalic acid, terephthalic acid, N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid, N,N-bis(2-hydroxyethyl)glycine, 3-[N,N-bis(2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, N-tris[hydroxylmethyl]methyl-3-aminopropanesulfonic acid, and N-tris[hydroxylmethyl]glycine.

8. The method of claim 5 wherein Z′ is poly(ethyleneglycol) with the number of ethyleneglycol monomer units greater than or equal to 20.

9. The method of claim 5 wherein the tissue is the heart and the image is a myocardial perfusion image.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: MALLINCKRODT LLC
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 034715/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2014
From: CANTRELL, GARY L.
To: MALLINCKRODT INC.
Reel/Frame 032502/0778 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →